Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Status:
Terminated
Trial end date:
2018-08-30
Target enrollment:
Participant gender:
Summary
Patients diagnosed with progressive and/or refractory solid malignancies, who have failed
conventional therapy, and have no available, potentially curative therapeutic options, will
be candidates for this Phase I/II study. Following confirmation of disease progression and/or
refractoriness, eligible patients who agree to participate and sign an informed consent form
will have their tumor cells/tissues and/or blood analyzed for the expression of a specific
panel of Tumor Associated Peptide Antigens (TAPAs), including Sp17, ropporin, AKAP-4, PTTG1,
Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1.